SlideShare une entreprise Scribd logo
1  sur  51
Herbal drug
regulations &
standardization
Content
 Quality control of herbal drugs as per WHO
guidelines.
 Herbal regulatory issue
 Safety parameters, toxicity concerns and herb- drug
interactions
 Herb patent case study
 Schedule T
 Schedule Y
 Proposed Schedule Z & shelf-life
 Standardization of marker of Phytoconstituents
Quality control of herbal drugs
(WHO guideline)
1. Authentication (stage of collection, parts of the plant
collected, regional status, botanical identity like
phyto-morphology, Microscopical and histological
analysis, taxonomical identity, etc.)
2. Foreign matter (herbs collected should be free from
soil, insect parts or animal excreta, etc.)
3. Organoleptic evaluation (sensory characters – taste,
appearance, odour, feel of the drug, etc.)
4. Tissues of diagnostic importance present in the drug
powder.
Quality control of herbal drugs
(WHO guideline)
5. Volatile matter
6. Moisture content determination
7. Chromatographic and spectroscopic evaluation.
9. Determination of heavy metals –
e.g. cadmium, lead, arsenic, etc.
9. Pesticide residue
10. Microbial contamination
11. Radioactive contamination
Herbal drug regulations
Regulation in India
 Herbal drugs are regulated under the Drug and Cosmetic
Act (D and C) 1940 and Rules 1945 in India, where
regulatory provisions for Ayurveda, Unani, Siddha
medicine are clearly laid down.
 Department of AYUSH is the regulatory authority and
mandate that any manufacture or marketing of herbal
drugs have to be done after obtaining manufacturing
license, as applicable.
 The D and C Act extends the control over licensing,
formulation composition, manufacture, labelling, packing,
quality, and export.
 Schedule “T” of the act lays down the good
manufacturing practice (GMP) requirements to be
followed for the manufacture of herbal medicines.
Regulation in India
 The official pharmacopoeias and formularies are
available for the quality standards of the medicines.
First schedule of the D and C Act has listed
authorized texts, which have to be followed for
licensing any herbal product under the two
categories: ASU drugs & Patent or proprietary
medicines.
 In India, traditional medicines are governed by the
Drugs and Cosmetics Act of 1940 and the Drugs and
Cosmetics Rules of 1945. They regulate the import,
manufacture, distribution and sale of drugs and
cosmetics.
Regulation in India
 In 1959, the Government of India recognized the traditional
Indian systems of medicine and amended the Drugs and
Cosmetics Act to include drugs which are derived from
traditional Indian medicine.
 No products derived from traditional systems may be
manufactured without a licence from the State Drug Control
Authorities.
 Patent and proprietary medicines derived from the traditional
systems must contain ingredients which are mentioned in the
recognized books of the above systems, as specified in the
Drugs and Cosmetics Act.
 The government is advised by a special committee and an
advisory board for Ayurvedic, Siddha and Unani drugs.
Pharmacopoeia committees have been constituted to prepare
pharmacopoeias for all these systems
Regulation in US
 The botanical products are classified as a drug, food
or a dietary supplement by the United States Food
and Drug Administration on the basis of the claims or
end use.
 A product that is used to prevent, diagnose, mitigate,
treat or cure a disease would fall under the category
of drug.
 If the intended use of a botanical product is to affect
the structure or function of the human body, it may
be classified as either a drug or a dietary supplement.
 As per FDA, the drug must be marketed under an
approved New Drug Application (NDA).
Regulation in US
 FDA regulates the dietary supplements under the
Dietary Supplement Health and Education Act of
1994.
 These do not require premarket approval and it’s the
responsibility of the marketer to ensure the safety
and labelling compliance of their products with the
regulations.
 The claims need to comply with the regulatory
guidelines issued by the FDA.
 The manufacturing of dietary supplements should be
done as per the current GMP for dietary supplements
Regulation in Australia
 Therapeutic Goods Administration, the regulatory
agency of Australia, regulate herbal products under
the category of complementary medicine.
 Ayurvedic medicine, traditional Chinese medicine, and
Australian indigenous medicines are all covered
under this category
 Complementary medicines which do not require
medical supervision are permitted and have to be
entered on the Australian Register for Therapeutic
Goods (ARTG) before marketing
Regulation in Australia
 The low-risk medicines require to be listed while the
medicines for comparatively higher risk therapeutic
conditions require registration on the ARTG.
 Only evidence-based claims which are entered on
the ARTG are allowed.
Regulation in Canada
 Since January 1, 2004, Health Canada regulates herbal
remedies and traditional medicines such as Ayurvedic
medicine, under the natural health products
regulations.
 The regulations mandate that a manufacturer, packer,
labeler or importer need to have a prior registration
with Health Canada before commencing any such
activity.
Regulation in Canada
 The process involves registration of the
manufacturing site/s along with the products.
Complete data on product composition,
standardization, stability, microbial and chemical
contaminant testing methods and tolerance limits,
safety and efficacy along with ingredient
characterization, quantification by assay or by input
needs to be submitted to Natural Health Product
Directorate (NHPD).
 The authority mandate that NHPs must comply with
the contaminant limits and must be manufactured as
per the GMP norms
Regulation in European union
 The European Medicine Agency have laid down two
ways of registration of herbal medicinal products:
 (1) A full marketing authorization by submission of a
dossier, which provides the information on quality,
safety and efficacy of the medicinal products
including the physicochemical, biological or microbial
tests and pharmacological, toxicological and clinical
trials data; under directive 2001/83/EC
Regulation in European union
 (2) For traditional herbal medicinal products, which
do not require medical supervision, and where
evidence of long traditional of use of medicinal
products exists, and adequate scientific literature to
demonstrate a well-established medicinal use cannot
be provided, a simplified procedure under directive
2004/24/EC exists.
 The evidence of traditional use is accepted as
evidence of efficacy of the product. However,
authorities may still ask for evidence to support
safety.
Regulation in European union
 Quality control requirements require physicochemical and
microbiological tests to be included in the product
specifications. The product should comply to the quality
standards in relevant pharmacopoeias of the member
state or European Pharmacopoeia.
 The bibliographic evidence should support that the
product has been in medicinal use for at least 30 years
out including at least 15 years within the European
community.
 The application for traditional use registration shall be
referred to the Committee for Herbal Medicinal Products,
if the product has been in the community for less than 15
years, but otherwise qualifies for the simplified
registration procedure under the directive.
Herb drug interactions
 Many medicinal herbs and pharmaceutical drugs are
therapeutic at one dose and toxic at another.
 Interactions between herbs and drugs may increase
or decrease the pharmacological or toxicological
effects of either component.
 Synergistic therapeutic effects may complicate the
dosing of long-term medications-
 E.g. herbs traditionally used to decrease glucose
concentrations in diabetes1 could theoretically
precipitate hypoglycaemia if taken in combination
with conventional drugs.
Herb drug interactions
 E.g. herbs traditionally used to decrease glucose
concentrations in diabetes1 could theoretically
precipitate hypoglycaemia if taken in combination
with conventional drugs.
 Herbal medicines are ubiquitous: the dearth of
reports of adverse events and interactions probably
reflects a combination of under-reporting and the
benign nature of most herbs used.
 increase or decrease the effect of a blood thinner
such as Warfarin and lead to either a bleeding
episode or formation of a dangerous clot;
Herb drug interactions
 decrease the effect of a blood pressure medication,
leading to high blood pressure and a stroke;
 decrease the effect of an anti-infection agent, letting
the infection get out of control; or
 increase the effect of an anti-diabetes drug and
plunge blood sugar to dangerously low levels.
Herb drug interactions
Garlic
 Allium sativum (garlic) decreased the area under the
plasma concentration-time curve (AUC) and
maximum plasma concentration of saquinavir, but
not ritonavir and paracetamol (acetaminophen), in
volunteers.
 A. sativum increased the clotting time and
international normalised ratio of warfarin and caused
hypoglycaemia when taken with chlorpropamide.
Herb drug interactions
Ginkgo
 Ginkgo biloba (ginkgo) caused bleeding when
combined with warfarin or aspirin (acetylsalicylic
acid), raised blood pressure when combined with a
thiazide diuretic and even caused coma when
combined with trazodone in patients.
Herb drug interactions
Ginseng
 Panax ginseng (ginseng) reduced the blood
concentrations of alcohol (ethanol) and warfarin, and
induced mania when used concomitantly with
phenelzine, but ginseng increased the efficacy of
influenza vaccination.
Herb drug interactions
St. john’s wort
 Hypericum perforatum (hypericum; St John's wort)
decreased the blood concentrations of ciclosporin
(cyclosporin), midazolam, tacrolimus, amitriptyline,
digoxin, indinavir, warfarin, phenprocoumon and
theophylline, but did not alter the pharmacokinetics
of carbamazepine, pravastatin, mycophenolate
mofetil and dextromethorphan.
Herb drug interactions
St. john’s wort
 Cases have been reported where decreased
ciclosporin concentrations led to organ rejection.
Hypericum also caused breakthrough bleeding and
unplanned pregnancies when used concomitantly
with oral contraceptives.
 It also caused serotonin syndrome when used in
combination with selective serotonin reuptake
inhibitors (e.g. sertraline and paroxetine).
Patent case study
 Pharmaceutical compositions comprising hemp and
turmeric to treat pain and inflammation
 WO 2015171445 A1
 ABSTRACT
 The present invention comprises compositions
comprising therapeutically effective amounts of CBD
and curcumin in various combinations to treat pain.
CBD and curcumin are preferably from natural
sources. A method of using the combination of CBD
and curcumin compositions to treat pain is also
described.
Patent case study
 Publication number WO2015171445 A1
 Publication type Application
 Application number PCT/US2015/028718
 Publication date 12 Nov 2015
 Filing date 1 May 2015
 Priority date 6 May 2014
 Inventors Mewa Singh
 Applicant Mewa Singh
 Export Citation BiBTeX, EndNote, RefMan
Patent case study
WHAT IS CLAIMED IS:
 1. A composition for treating pain comprising a
therapeutically effective amount of cannabidiol (CBD)
and curcumin.
 2. The composition of claim 1, further comprising at
least one of: magnesium or ginger.
 3. The composition of claim 1, wherein the CBD and
curcumin comprises natural sources of CBD and
curcumin.
 4. The composition of claim 1 , wherein the natural
source of CBD comprises CBD producing hemp and
the natural source of curcumin comprises turmeric.
Patent case study
5. The composition of claim 4, wherein the CBD comprises
a liquid or a powder extract of a cannabis plant and the
curcumin comprises a liquid or a powder extract from a
turmeric root.
6. The composition of claim 5, wherein the CBD extract
comprises at least 80% (w/w) CBD to total cannabinoid
content.
7. The composition of claim 5, wherein the curcumin
extract comprises at least 2% by weight curcuminoid
content.
8. The composition of claim 5, wherein the weight ratio of
CBD extract to curcumin extract comprises about 1 : 1 to
about 1 :5.
Patent case study
9. The composition of claim 5, wherein the weight ratio of
CBD in the CBD extract and curcuminoid in the curcumin
extract comprises about 1 : 1 to about 1 : 10.
10. The composition of claim 5, wherein the composition
comprises a water soluble dosage form.
11. The dosage form of claim 10, wherein the dosage form
comprises a capsule, tablet or liquid.
12. The dosage form of claim 11 , wherein the dosage form
comprises a capsule.
Patent case study
13. A method of treating pain comprising: a) selecting a
patient in need of treatment for pain; b) administering to
the patient a therapeutically effective amount of CBD and
curcumin, wherein the patient is treated.
14. The method as claimed in claim 13, wherein the pain
comprises acute pain, chronic pain, or acute and chronic
pain.
15. A method of treating pain comprising administering to
a patient the composition of claim 1.
16. A method of treating pain comprising administering to
a patient the composition of claim 2.
Patent case study
17. A method of treating pain comprising administering to
a patient the composition of claim 4.
18. A method of treating pain comprising administering to
a patient the composition of claim 5.
19. A method of treating pain comprising administering to
a patient the capsule of claim 12.
Schedule T
The Good Manufacturing Practices (GMP) are prescribed
as follows in Part I and Part II to
ensure that:
I. Raw materials used in the manufacture of drugs are
authentic, of prescribed quality and are free from
contamination.
II. The manufacturing process is as has been
prescribed to maintain the standards.
III. Adequate quality control measures are adopted.
IV. The manufactured drug which is released for sale is
of acceptable quality.
Schedule T
V. To achieve the objectives listed above, each licensee
shall evolve methodology and procedures for
following the prescribed process of manufacture of
drugs which should be documented as a manual and
kept for reference and inspection. However, under
IMCC Act 1970 registered Vaidyas, Siddhas and
Hakeems who prepare medicines on their own to
dispense to their patients and not selling such drugs
in the market are exempted from the purview of
G.M.P.
Schedule T
 PART-I
 GOOD MANUFACTRING PRACTICES
 Factory Premises:
 The manufacturing plant should have adequate space
for:-
(i) Receiving and storing raw material
(ii) Manufacturing process areas
(iii) Quality control section
(iv) Finished goods store
(v) Office
(vi) Rejected goods/drugs store
Schedule T
 General Requirements:
 Location and surroundings
 Buildings
 Water supply
 Disposal of waste
 Containers’ cleaning
 Stores
 Raw materials
 Packaging material
 Finished goods stores
Schedule T
 Working space
 Heath, clothing, sanitation and hygiene of workers
 Medical services
 Machinery and equipment's
 Batch manufacturing records
 Distribution records
 Record of market complaints
 Quality control
Schedule T
 Requirement for Sterile product
 Manufacturing areas
 Precautions against contamination and mix
Schedule T
 Requirement for Space for ASU
 200 sq. feet: Asava, Arishta, Churna /
Nasya/Manjan/Lepa/Kwath Churn Sufoof (powder)
 150 sq. feet: Kupi pakava/Ksara/ Parpati/Lavana Bhasma
Satva/Sindura Karpu/ Uppu /Param, Panak, Syrup /
Pravahi Kwath Manapaku,
 100 sq. feet: Anjana/Pisti, Pills/Vati /Gutika, Matirai and
tablets, Kajal, Capsule, Marham, ointment,
Pak/Avaleh/Khand/ Modak/Lakayam, Ark Tinir, Sura,
Taila, Ghrit ney, Aschyotan / Netra Malham, Panir/Karn
Bindu/Nasabindu, Habb (Pills) and tablets, Arq,
Schedule Y for Herbal Drugs
 All of the fundamental ethical principles of human participation in
research apply equally to herbal remedies and research involving
these compounds.
 Consent must be obtained, subject selection must be equitable,
risks and benefits must be weighed and must be favourable to the
potential participant, and experimental design must be sound.
 Concerns that particularly apply to clinical trials with herbal
products include:
 Product adulteration (has it been documented?)
 Interactions between herbal remedies and other entities (rarely
understood)
 Reproductive and organ toxicity data (may be minimal)
 Prior dose finding (likely to be incomplete).
Schedule Y for Herbal Drugs
 Category 1: already in use for more than 5 years
 Category 2: in use for less than 5 years
 Category 3: new medicines.
 For the herbal remedies and medicinal plants that are to be
clinically evaluated for use in the Allopathic System and which may
later be used in allopathic hospitals, the procedures laid down by
the office of the Drugs Controller General of India for allopathic
drugs should be followed.
 When an extract of a plant or a compound isolated from the plant
has to be clinically evaluated for a therapeutic effect not originally
described in the texts of traditional systems or, the method of
preparation is different, it has to be treated as a new substance or
new chemical entity (NCE) and the same type of acute, sub acute
and chronic toxicity data will have to be generated as required by
the regulatory authority before it is cleared for clinical evaluation.
Schedule Y for Herbal Drugs
 An extract or a compound isolated from a plant, which has never
been in use before and has not ever been mentioned in ancient
literature, should be treated as a new drug, and therefore, should
undergo all regulatory requirements before being evaluated
clinically.
 The document also provides general guidelines on clinical trials of
herbals, toxicity studies, need for standardization, and compliance
with GCP in all clinical trials.
 Some of the recommendations are:
 Clinical trials should be carried out with herbal preparations only
after standardization and identification of markers to ensure that
the substances being evaluated are always the same.
 Plants and herbal remedies should be prepared strictly in the same
way as described in the literature while incorporating GMP norms
for standardization.
Schedule Y for Herbal Drugs
 Herbal remedies, Phase 1 studies must be undertaken to check
Maximum tolerarated dose (MTD) & Early Measurement of Drug
activity.
 If there are reports suggesting toxicity or when the herbal
preparation is to be used for more than 3 months, toxicity studies
(4-6 weeks toxicity study in 2 species) are needed for phase 2 trials.
 For Phase 3 trial toxicity studies (4-6 weeks toxicity study in 2
species) are needed.
 Ethical guidelines (patient information, informed consent, protection
of vulnerable populations etc) for biomedical research should be
followed.
 Clinical trials should to be approved by the appropriate scientific
and ethical committees of the concerned Institutes.
 Clinical trials should be carried out only when a competent
Ayurvedic, Siddha or Unani physician is a co-investigator.
Herbal Drug Regulations
 Schedule Z: Proposed: Requirements and Guidelines for permission to
manufacture of ASU Drugs for sale or to undertake clinical trials
 Updated shelf life
Marker standardization
 Volatile Oil: Eugenol
 Glycoside: Digitoxin
 Resin: Curcumin
 Flavonoids: Quercetin
 Irridoids: Gentiopicroside
Marker standardization
Volatile Oil: Eugenol
 Species: Cinnamomum zeylanicum
 Eugenia caryophyllus
 TLC Mobile Phase
 Toluene: Ethyl acetate (93:7)
 Detection: Vanillin H2SO4 & Visible light
 Observation: Pinkish red spot
 Rf value: 0.9
 Eugenol oil on treatment with KOH, produces Potassium
eugenate crystals
Marker standardization
Glycoside: Digitoxin
 Species: Digitalis lanata
 Digitalis purpurea
 TLC Mobile Phase
 Ethyl acetate: Methanol: Water (81:11:8)
 Detection: Kedde reagent & Visible light
 Observation: Grey to Violet grey color spot
 Detection: SbCl3 & UV-365
 Observation: Dark blue fluorescence
 Rf value: 0.05-0.95
 Keller-killiani test for Cardiac glycoside
Marker standardization
Glycoside: Glycyrrhizin (K+ salt)
 Species: Glycyrrhiza glabara
 TLC Mobile Phase
 Chloroform: Methanol: Water (64:50:10)
 Detection: UV 254 nm
 Rf value: 0.25-0.3- Glycyrrhizin
 Detection: Anisaldehyde H2SO4 reagent
 Observation: Pink-violet spot
 Rf value: 0.24- Glycyrrhizin
 0.6-0.8 - Liquiritin
Marker standardization
Resin: Curcumin
 Species: Curcuma longs
 Curcuma domestica
 TLC Mobile Phase
 Cholorofrom: Ethanol: Glacial acetic acid (95:5:1)
 Detection: UV-365
 Observation: Yellow
 Rf value: 0.3 – bisdemethoxycurcumin
 0.5-0.55 – demethoxycurcumin
 0.6 – curcumin
Marker standardization
Flavonoids: Rutin
 Species:
 TLC Mobile Phase
 Ethyl acetate: Formic acid: Glacial acetic acid: Water
(100:11:11:26)
 Detection: UV-365
 Observation: Yellow orange
 Rf value: 0.4 – Rutin
 Shinoda test for Flavonoids
Marker standardization
Irridoids: Gentiopicroside
 Species: Gentiana lutea
 TLC Mobile Phase
 Ethyl acetate: Methanol: Water (77:15:8)
 Detection: Vanillin H2SO4 & Visible light
 Observation: brown-violet spot
 Rf value: 0.45 (gentiopicroside)
 Detection: UV 245 nm
 Rf value: 0.4 – swetiamarine
 0.45 – gentiopicroside
 0.8 – amarogentin

Contenu connexe

Tendances

Regulation of herbal drugs in india
Regulation of herbal drugs in indiaRegulation of herbal drugs in india
Regulation of herbal drugs in indiaRicha Patel
 
Regulation of herbal drugs
Regulation of herbal drugsRegulation of herbal drugs
Regulation of herbal drugsShaistaAhmed8
 
Quality Assurance in Herbal Drug Industry
Quality Assurance in Herbal Drug IndustryQuality Assurance in Herbal Drug Industry
Quality Assurance in Herbal Drug IndustryAshwani Dhingra
 
Monographs Of Herbal Drugs and Comparative Study In Various Pharmacopoeias.
Monographs Of Herbal Drugs and Comparative Study In Various Pharmacopoeias.Monographs Of Herbal Drugs and Comparative Study In Various Pharmacopoeias.
Monographs Of Herbal Drugs and Comparative Study In Various Pharmacopoeias.VidyaNani
 
Effect of Herbal Medicine on Clinical Laboratory Testing
Effect of Herbal Medicine on Clinical Laboratory TestingEffect of Herbal Medicine on Clinical Laboratory Testing
Effect of Herbal Medicine on Clinical Laboratory TestingManjusha Kondepudi
 
Regulatory requirement for setting herbal drug industry
Regulatory requirement for setting herbal drug industryRegulatory requirement for setting herbal drug industry
Regulatory requirement for setting herbal drug industryRAGHAV DOGRA
 
stability testing
stability testingstability testing
stability testingphcognosy
 
Patenting of natural products by Dr.U.Srinivasa , Professor, Srinivas college...
Patenting of natural products by Dr.U.Srinivasa , Professor, Srinivas college...Patenting of natural products by Dr.U.Srinivasa , Professor, Srinivas college...
Patenting of natural products by Dr.U.Srinivasa , Professor, Srinivas college...ummanabadsrinivas
 
Regulatory requirement for herbal medicines.pptx
Regulatory requirement for herbal medicines.pptxRegulatory requirement for herbal medicines.pptx
Regulatory requirement for herbal medicines.pptxEasy Concept
 
Herbal drug industry by pooja
Herbal drug industry by poojaHerbal drug industry by pooja
Herbal drug industry by poojaPOOJA KHANPARA
 
STABILITY TESTING OF HERBAL NATURAL PRODUCTS
STABILITY TESTING OF HERBAL NATURAL PRODUCTSSTABILITY TESTING OF HERBAL NATURAL PRODUCTS
STABILITY TESTING OF HERBAL NATURAL PRODUCTSTejaswini Chandra
 
INDIAN AND INTERNATIONAL PATENT LAW AS APPLICABLE TO HERBAL AND NATURAL PRODUCTS
INDIAN AND INTERNATIONAL PATENT LAW AS APPLICABLE TO HERBAL AND NATURAL PRODUCTSINDIAN AND INTERNATIONAL PATENT LAW AS APPLICABLE TO HERBAL AND NATURAL PRODUCTS
INDIAN AND INTERNATIONAL PATENT LAW AS APPLICABLE TO HERBAL AND NATURAL PRODUCTSTejaswini Chandra
 
Regulatory issues regulations in india asu
Regulatory issues   regulations in india asuRegulatory issues   regulations in india asu
Regulatory issues regulations in india asuMohammad Khalid
 
Preparation of documents for NDA.pptx
Preparation of documents for NDA.pptxPreparation of documents for NDA.pptx
Preparation of documents for NDA.pptxEasy Concept
 

Tendances (20)

Regulation of herbal drugs in india
Regulation of herbal drugs in indiaRegulation of herbal drugs in india
Regulation of herbal drugs in india
 
Good manufacturing practice
Good manufacturing practiceGood manufacturing practice
Good manufacturing practice
 
Regulatory aspect of herbal medicines
Regulatory aspect of herbal medicinesRegulatory aspect of herbal medicines
Regulatory aspect of herbal medicines
 
Regulation of herbal drugs
Regulation of herbal drugsRegulation of herbal drugs
Regulation of herbal drugs
 
Quality Assurance in Herbal Drug Industry
Quality Assurance in Herbal Drug IndustryQuality Assurance in Herbal Drug Industry
Quality Assurance in Herbal Drug Industry
 
Monographs Of Herbal Drugs and Comparative Study In Various Pharmacopoeias.
Monographs Of Herbal Drugs and Comparative Study In Various Pharmacopoeias.Monographs Of Herbal Drugs and Comparative Study In Various Pharmacopoeias.
Monographs Of Herbal Drugs and Comparative Study In Various Pharmacopoeias.
 
Effect of Herbal Medicine on Clinical Laboratory Testing
Effect of Herbal Medicine on Clinical Laboratory TestingEffect of Herbal Medicine on Clinical Laboratory Testing
Effect of Herbal Medicine on Clinical Laboratory Testing
 
Regulatory requirement for setting herbal drug industry
Regulatory requirement for setting herbal drug industryRegulatory requirement for setting herbal drug industry
Regulatory requirement for setting herbal drug industry
 
stability testing
stability testingstability testing
stability testing
 
MONOGRAPHS OF HERBAL DRUGS
MONOGRAPHS OF HERBAL DRUGS MONOGRAPHS OF HERBAL DRUGS
MONOGRAPHS OF HERBAL DRUGS
 
Patenting of natural products by Dr.U.Srinivasa , Professor, Srinivas college...
Patenting of natural products by Dr.U.Srinivasa , Professor, Srinivas college...Patenting of natural products by Dr.U.Srinivasa , Professor, Srinivas college...
Patenting of natural products by Dr.U.Srinivasa , Professor, Srinivas college...
 
Herbal Drug Industry
Herbal Drug IndustryHerbal Drug Industry
Herbal Drug Industry
 
Regulatory requirement for herbal medicines.pptx
Regulatory requirement for herbal medicines.pptxRegulatory requirement for herbal medicines.pptx
Regulatory requirement for herbal medicines.pptx
 
Herbal drug industry by pooja
Herbal drug industry by poojaHerbal drug industry by pooja
Herbal drug industry by pooja
 
STABILITY TESTING OF HERBAL NATURAL PRODUCTS
STABILITY TESTING OF HERBAL NATURAL PRODUCTSSTABILITY TESTING OF HERBAL NATURAL PRODUCTS
STABILITY TESTING OF HERBAL NATURAL PRODUCTS
 
EU guideline.pptx
EU guideline.pptxEU guideline.pptx
EU guideline.pptx
 
Herbal remedies
Herbal remediesHerbal remedies
Herbal remedies
 
INDIAN AND INTERNATIONAL PATENT LAW AS APPLICABLE TO HERBAL AND NATURAL PRODUCTS
INDIAN AND INTERNATIONAL PATENT LAW AS APPLICABLE TO HERBAL AND NATURAL PRODUCTSINDIAN AND INTERNATIONAL PATENT LAW AS APPLICABLE TO HERBAL AND NATURAL PRODUCTS
INDIAN AND INTERNATIONAL PATENT LAW AS APPLICABLE TO HERBAL AND NATURAL PRODUCTS
 
Regulatory issues regulations in india asu
Regulatory issues   regulations in india asuRegulatory issues   regulations in india asu
Regulatory issues regulations in india asu
 
Preparation of documents for NDA.pptx
Preparation of documents for NDA.pptxPreparation of documents for NDA.pptx
Preparation of documents for NDA.pptx
 

En vedette (7)

NATURAL DYES
NATURAL DYESNATURAL DYES
NATURAL DYES
 
Indian Mustard Bee Pollen Exhibits High Antioxidant Content
Indian Mustard Bee Pollen Exhibits High Antioxidant ContentIndian Mustard Bee Pollen Exhibits High Antioxidant Content
Indian Mustard Bee Pollen Exhibits High Antioxidant Content
 
Nutrceuticals
NutrceuticalsNutrceuticals
Nutrceuticals
 
Nutraceuticals
NutraceuticalsNutraceuticals
Nutraceuticals
 
Bee pollen
Bee pollenBee pollen
Bee pollen
 
Mushroom
MushroomMushroom
Mushroom
 
Cosmeceuticals....d.d.
Cosmeceuticals....d.d.Cosmeceuticals....d.d.
Cosmeceuticals....d.d.
 

Similaire à Herbal drug regulations

Herbal drug regulations and standardisation
Herbal drug regulations and standardisationHerbal drug regulations and standardisation
Herbal drug regulations and standardisationRavish Yadav
 
Phytopharmacovigilance by pooja
Phytopharmacovigilance by pooja Phytopharmacovigilance by pooja
Phytopharmacovigilance by pooja POOJA KHANPARA
 
India Ayurvedic.pdf Ayurveda Samhitha ayurvedic
India Ayurvedic.pdf Ayurveda Samhitha ayurvedicIndia Ayurvedic.pdf Ayurveda Samhitha ayurvedic
India Ayurvedic.pdf Ayurveda Samhitha ayurvedicKrishMotupalli
 
Regulatory requirements on herbal drugs understading the global perspective
Regulatory requirements on herbal drugs   understading the global perspectiveRegulatory requirements on herbal drugs   understading the global perspective
Regulatory requirements on herbal drugs understading the global perspectivessuserd3ff07
 
IRJET- Regulation on Herbal Product used as Medicine around the World: A Review
IRJET- Regulation on Herbal Product used as Medicine around the World: A ReviewIRJET- Regulation on Herbal Product used as Medicine around the World: A Review
IRJET- Regulation on Herbal Product used as Medicine around the World: A ReviewIRJET Journal
 
Regulatory requirements for herbal medicines
Regulatory requirements for herbal medicinesRegulatory requirements for herbal medicines
Regulatory requirements for herbal medicinesDr-Jitendra Patel
 
Quality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in IndiaQuality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in IndiaS S N D Balakrishna Ch
 
Biologics and herbals.pptx
Biologics and herbals.pptxBiologics and herbals.pptx
Biologics and herbals.pptxZeelshah2258
 
regulation of herbal products
regulation of herbal productsregulation of herbal products
regulation of herbal productsjatin singla
 
A Study report on various HP.pptx
A Study report on various HP.pptxA Study report on various HP.pptx
A Study report on various HP.pptxSohailSheikh48
 
UNIT-1-L-1,2,3-converted.pptx
UNIT-1-L-1,2,3-converted.pptxUNIT-1-L-1,2,3-converted.pptx
UNIT-1-L-1,2,3-converted.pptxmonika kaurav
 
Standardisation and QC of Ayurvedic Drugs RARC Dimapur 04.03.2-23.pptx
Standardisation and QC of Ayurvedic Drugs RARC Dimapur 04.03.2-23.pptxStandardisation and QC of Ayurvedic Drugs RARC Dimapur 04.03.2-23.pptx
Standardisation and QC of Ayurvedic Drugs RARC Dimapur 04.03.2-23.pptxravindrasinghm
 
regulatory approval process of drug, cosmetic and herbals in canada
regulatory approval process of drug, cosmetic and herbals  in canada regulatory approval process of drug, cosmetic and herbals  in canada
regulatory approval process of drug, cosmetic and herbals in canada Richa Patel
 

Similaire à Herbal drug regulations (20)

Herbal drug regulations and standardisation
Herbal drug regulations and standardisationHerbal drug regulations and standardisation
Herbal drug regulations and standardisation
 
Phytopharmacovigilance by pooja
Phytopharmacovigilance by pooja Phytopharmacovigilance by pooja
Phytopharmacovigilance by pooja
 
India Ayurvedic.pdf Ayurveda Samhitha ayurvedic
India Ayurvedic.pdf Ayurveda Samhitha ayurvedicIndia Ayurvedic.pdf Ayurveda Samhitha ayurvedic
India Ayurvedic.pdf Ayurveda Samhitha ayurvedic
 
Regulatory requirements on herbal drugs understading the global perspective
Regulatory requirements on herbal drugs   understading the global perspectiveRegulatory requirements on herbal drugs   understading the global perspective
Regulatory requirements on herbal drugs understading the global perspective
 
IRJET- Regulation on Herbal Product used as Medicine around the World: A Review
IRJET- Regulation on Herbal Product used as Medicine around the World: A ReviewIRJET- Regulation on Herbal Product used as Medicine around the World: A Review
IRJET- Regulation on Herbal Product used as Medicine around the World: A Review
 
Herbal Cough Remedies
Herbal Cough RemediesHerbal Cough Remedies
Herbal Cough Remedies
 
rahb module 5.pptx
rahb module 5.pptxrahb module 5.pptx
rahb module 5.pptx
 
Law No. 105/2016/QH13: LAW ON PHARMACY dated April 06, 2016
Law No. 105/2016/QH13: LAW ON PHARMACY dated April 06, 2016Law No. 105/2016/QH13: LAW ON PHARMACY dated April 06, 2016
Law No. 105/2016/QH13: LAW ON PHARMACY dated April 06, 2016
 
Regulatory requirements for herbal medicines
Regulatory requirements for herbal medicinesRegulatory requirements for herbal medicines
Regulatory requirements for herbal medicines
 
Quality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in IndiaQuality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in India
 
Evaluation of herbal drugs
Evaluation of herbal drugsEvaluation of herbal drugs
Evaluation of herbal drugs
 
Biologics and herbals.pptx
Biologics and herbals.pptxBiologics and herbals.pptx
Biologics and herbals.pptx
 
D & C Act 1940
D & C Act 1940D & C Act 1940
D & C Act 1940
 
regulation of herbal products
regulation of herbal productsregulation of herbal products
regulation of herbal products
 
A Study report on various HP.pptx
A Study report on various HP.pptxA Study report on various HP.pptx
A Study report on various HP.pptx
 
MONOGRAPH.pptx
MONOGRAPH.pptxMONOGRAPH.pptx
MONOGRAPH.pptx
 
UNIT-1-L-1,2,3-converted.pptx
UNIT-1-L-1,2,3-converted.pptxUNIT-1-L-1,2,3-converted.pptx
UNIT-1-L-1,2,3-converted.pptx
 
Standardisation and QC of Ayurvedic Drugs RARC Dimapur 04.03.2-23.pptx
Standardisation and QC of Ayurvedic Drugs RARC Dimapur 04.03.2-23.pptxStandardisation and QC of Ayurvedic Drugs RARC Dimapur 04.03.2-23.pptx
Standardisation and QC of Ayurvedic Drugs RARC Dimapur 04.03.2-23.pptx
 
Ethics chapter
Ethics chapterEthics chapter
Ethics chapter
 
regulatory approval process of drug, cosmetic and herbals in canada
regulatory approval process of drug, cosmetic and herbals  in canada regulatory approval process of drug, cosmetic and herbals  in canada
regulatory approval process of drug, cosmetic and herbals in canada
 

Plus de Dr Priyanka Goswami (20)

Vaccine safety surveillance
Vaccine safety surveillanceVaccine safety surveillance
Vaccine safety surveillance
 
Non nutritive sweeteners
Non nutritive sweetenersNon nutritive sweeteners
Non nutritive sweeteners
 
Phytopharmaceuticals
PhytopharmaceuticalsPhytopharmaceuticals
Phytopharmaceuticals
 
Herbal cosmeceuticals
Herbal cosmeceuticalsHerbal cosmeceuticals
Herbal cosmeceuticals
 
Phytopharmaceutical technology terms
Phytopharmaceutical technology termsPhytopharmaceutical technology terms
Phytopharmaceutical technology terms
 
Glycoprotein
GlycoproteinGlycoprotein
Glycoprotein
 
Panch karma
Panch karmaPanch karma
Panch karma
 
Herbal formulations
Herbal formulationsHerbal formulations
Herbal formulations
 
Herbal excipients
Herbal excipientsHerbal excipients
Herbal excipients
 
Herbal cosmetics
Herbal cosmeticsHerbal cosmetics
Herbal cosmetics
 
Powder Characters_Pharmacognosy
Powder Characters_PharmacognosyPowder Characters_Pharmacognosy
Powder Characters_Pharmacognosy
 
Flavonoids
FlavonoidsFlavonoids
Flavonoids
 
Traditional drugs
Traditional drugsTraditional drugs
Traditional drugs
 
Carotenoids as Nutraceuticals
Carotenoids as NutraceuticalsCarotenoids as Nutraceuticals
Carotenoids as Nutraceuticals
 
Nutraceuticals
NutraceuticalsNutraceuticals
Nutraceuticals
 
Pharmacognosy Simplified
Pharmacognosy SimplifiedPharmacognosy Simplified
Pharmacognosy Simplified
 
Terpenoid iridoid
Terpenoid iridoidTerpenoid iridoid
Terpenoid iridoid
 
Polyketide lignan-phenylpropanoids
Polyketide lignan-phenylpropanoidsPolyketide lignan-phenylpropanoids
Polyketide lignan-phenylpropanoids
 
Enzymes of Natural Origin
Enzymes of Natural OriginEnzymes of Natural Origin
Enzymes of Natural Origin
 
Fibers of Natural Origin
Fibers of Natural OriginFibers of Natural Origin
Fibers of Natural Origin
 

Dernier

AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
AI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsAI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsEmily Kunka, MS, CCRP
 
Employability skills, work experience presentation
Employability skills, work experience presentationEmployability skills, work experience presentation
Employability skills, work experience presentationmarwaahmad357
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Understanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essUnderstanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essAbhishekKumar524514
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 

Dernier (20)

AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
AI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsAI in Action: Elevating Patient Insights
AI in Action: Elevating Patient Insights
 
Employability skills, work experience presentation
Employability skills, work experience presentationEmployability skills, work experience presentation
Employability skills, work experience presentation
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Understanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essUnderstanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well ess
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 

Herbal drug regulations

  • 2. Content  Quality control of herbal drugs as per WHO guidelines.  Herbal regulatory issue  Safety parameters, toxicity concerns and herb- drug interactions  Herb patent case study  Schedule T  Schedule Y  Proposed Schedule Z & shelf-life  Standardization of marker of Phytoconstituents
  • 3. Quality control of herbal drugs (WHO guideline) 1. Authentication (stage of collection, parts of the plant collected, regional status, botanical identity like phyto-morphology, Microscopical and histological analysis, taxonomical identity, etc.) 2. Foreign matter (herbs collected should be free from soil, insect parts or animal excreta, etc.) 3. Organoleptic evaluation (sensory characters – taste, appearance, odour, feel of the drug, etc.) 4. Tissues of diagnostic importance present in the drug powder.
  • 4. Quality control of herbal drugs (WHO guideline) 5. Volatile matter 6. Moisture content determination 7. Chromatographic and spectroscopic evaluation. 9. Determination of heavy metals – e.g. cadmium, lead, arsenic, etc. 9. Pesticide residue 10. Microbial contamination 11. Radioactive contamination
  • 6. Regulation in India  Herbal drugs are regulated under the Drug and Cosmetic Act (D and C) 1940 and Rules 1945 in India, where regulatory provisions for Ayurveda, Unani, Siddha medicine are clearly laid down.  Department of AYUSH is the regulatory authority and mandate that any manufacture or marketing of herbal drugs have to be done after obtaining manufacturing license, as applicable.  The D and C Act extends the control over licensing, formulation composition, manufacture, labelling, packing, quality, and export.  Schedule “T” of the act lays down the good manufacturing practice (GMP) requirements to be followed for the manufacture of herbal medicines.
  • 7. Regulation in India  The official pharmacopoeias and formularies are available for the quality standards of the medicines. First schedule of the D and C Act has listed authorized texts, which have to be followed for licensing any herbal product under the two categories: ASU drugs & Patent or proprietary medicines.  In India, traditional medicines are governed by the Drugs and Cosmetics Act of 1940 and the Drugs and Cosmetics Rules of 1945. They regulate the import, manufacture, distribution and sale of drugs and cosmetics.
  • 8. Regulation in India  In 1959, the Government of India recognized the traditional Indian systems of medicine and amended the Drugs and Cosmetics Act to include drugs which are derived from traditional Indian medicine.  No products derived from traditional systems may be manufactured without a licence from the State Drug Control Authorities.  Patent and proprietary medicines derived from the traditional systems must contain ingredients which are mentioned in the recognized books of the above systems, as specified in the Drugs and Cosmetics Act.  The government is advised by a special committee and an advisory board for Ayurvedic, Siddha and Unani drugs. Pharmacopoeia committees have been constituted to prepare pharmacopoeias for all these systems
  • 9. Regulation in US  The botanical products are classified as a drug, food or a dietary supplement by the United States Food and Drug Administration on the basis of the claims or end use.  A product that is used to prevent, diagnose, mitigate, treat or cure a disease would fall under the category of drug.  If the intended use of a botanical product is to affect the structure or function of the human body, it may be classified as either a drug or a dietary supplement.  As per FDA, the drug must be marketed under an approved New Drug Application (NDA).
  • 10. Regulation in US  FDA regulates the dietary supplements under the Dietary Supplement Health and Education Act of 1994.  These do not require premarket approval and it’s the responsibility of the marketer to ensure the safety and labelling compliance of their products with the regulations.  The claims need to comply with the regulatory guidelines issued by the FDA.  The manufacturing of dietary supplements should be done as per the current GMP for dietary supplements
  • 11. Regulation in Australia  Therapeutic Goods Administration, the regulatory agency of Australia, regulate herbal products under the category of complementary medicine.  Ayurvedic medicine, traditional Chinese medicine, and Australian indigenous medicines are all covered under this category  Complementary medicines which do not require medical supervision are permitted and have to be entered on the Australian Register for Therapeutic Goods (ARTG) before marketing
  • 12. Regulation in Australia  The low-risk medicines require to be listed while the medicines for comparatively higher risk therapeutic conditions require registration on the ARTG.  Only evidence-based claims which are entered on the ARTG are allowed.
  • 13. Regulation in Canada  Since January 1, 2004, Health Canada regulates herbal remedies and traditional medicines such as Ayurvedic medicine, under the natural health products regulations.  The regulations mandate that a manufacturer, packer, labeler or importer need to have a prior registration with Health Canada before commencing any such activity.
  • 14. Regulation in Canada  The process involves registration of the manufacturing site/s along with the products. Complete data on product composition, standardization, stability, microbial and chemical contaminant testing methods and tolerance limits, safety and efficacy along with ingredient characterization, quantification by assay or by input needs to be submitted to Natural Health Product Directorate (NHPD).  The authority mandate that NHPs must comply with the contaminant limits and must be manufactured as per the GMP norms
  • 15. Regulation in European union  The European Medicine Agency have laid down two ways of registration of herbal medicinal products:  (1) A full marketing authorization by submission of a dossier, which provides the information on quality, safety and efficacy of the medicinal products including the physicochemical, biological or microbial tests and pharmacological, toxicological and clinical trials data; under directive 2001/83/EC
  • 16. Regulation in European union  (2) For traditional herbal medicinal products, which do not require medical supervision, and where evidence of long traditional of use of medicinal products exists, and adequate scientific literature to demonstrate a well-established medicinal use cannot be provided, a simplified procedure under directive 2004/24/EC exists.  The evidence of traditional use is accepted as evidence of efficacy of the product. However, authorities may still ask for evidence to support safety.
  • 17. Regulation in European union  Quality control requirements require physicochemical and microbiological tests to be included in the product specifications. The product should comply to the quality standards in relevant pharmacopoeias of the member state or European Pharmacopoeia.  The bibliographic evidence should support that the product has been in medicinal use for at least 30 years out including at least 15 years within the European community.  The application for traditional use registration shall be referred to the Committee for Herbal Medicinal Products, if the product has been in the community for less than 15 years, but otherwise qualifies for the simplified registration procedure under the directive.
  • 18. Herb drug interactions  Many medicinal herbs and pharmaceutical drugs are therapeutic at one dose and toxic at another.  Interactions between herbs and drugs may increase or decrease the pharmacological or toxicological effects of either component.  Synergistic therapeutic effects may complicate the dosing of long-term medications-  E.g. herbs traditionally used to decrease glucose concentrations in diabetes1 could theoretically precipitate hypoglycaemia if taken in combination with conventional drugs.
  • 19. Herb drug interactions  E.g. herbs traditionally used to decrease glucose concentrations in diabetes1 could theoretically precipitate hypoglycaemia if taken in combination with conventional drugs.  Herbal medicines are ubiquitous: the dearth of reports of adverse events and interactions probably reflects a combination of under-reporting and the benign nature of most herbs used.  increase or decrease the effect of a blood thinner such as Warfarin and lead to either a bleeding episode or formation of a dangerous clot;
  • 20. Herb drug interactions  decrease the effect of a blood pressure medication, leading to high blood pressure and a stroke;  decrease the effect of an anti-infection agent, letting the infection get out of control; or  increase the effect of an anti-diabetes drug and plunge blood sugar to dangerously low levels.
  • 21. Herb drug interactions Garlic  Allium sativum (garlic) decreased the area under the plasma concentration-time curve (AUC) and maximum plasma concentration of saquinavir, but not ritonavir and paracetamol (acetaminophen), in volunteers.  A. sativum increased the clotting time and international normalised ratio of warfarin and caused hypoglycaemia when taken with chlorpropamide.
  • 22. Herb drug interactions Ginkgo  Ginkgo biloba (ginkgo) caused bleeding when combined with warfarin or aspirin (acetylsalicylic acid), raised blood pressure when combined with a thiazide diuretic and even caused coma when combined with trazodone in patients.
  • 23. Herb drug interactions Ginseng  Panax ginseng (ginseng) reduced the blood concentrations of alcohol (ethanol) and warfarin, and induced mania when used concomitantly with phenelzine, but ginseng increased the efficacy of influenza vaccination.
  • 24. Herb drug interactions St. john’s wort  Hypericum perforatum (hypericum; St John's wort) decreased the blood concentrations of ciclosporin (cyclosporin), midazolam, tacrolimus, amitriptyline, digoxin, indinavir, warfarin, phenprocoumon and theophylline, but did not alter the pharmacokinetics of carbamazepine, pravastatin, mycophenolate mofetil and dextromethorphan.
  • 25. Herb drug interactions St. john’s wort  Cases have been reported where decreased ciclosporin concentrations led to organ rejection. Hypericum also caused breakthrough bleeding and unplanned pregnancies when used concomitantly with oral contraceptives.  It also caused serotonin syndrome when used in combination with selective serotonin reuptake inhibitors (e.g. sertraline and paroxetine).
  • 26. Patent case study  Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation  WO 2015171445 A1  ABSTRACT  The present invention comprises compositions comprising therapeutically effective amounts of CBD and curcumin in various combinations to treat pain. CBD and curcumin are preferably from natural sources. A method of using the combination of CBD and curcumin compositions to treat pain is also described.
  • 27. Patent case study  Publication number WO2015171445 A1  Publication type Application  Application number PCT/US2015/028718  Publication date 12 Nov 2015  Filing date 1 May 2015  Priority date 6 May 2014  Inventors Mewa Singh  Applicant Mewa Singh  Export Citation BiBTeX, EndNote, RefMan
  • 28. Patent case study WHAT IS CLAIMED IS:  1. A composition for treating pain comprising a therapeutically effective amount of cannabidiol (CBD) and curcumin.  2. The composition of claim 1, further comprising at least one of: magnesium or ginger.  3. The composition of claim 1, wherein the CBD and curcumin comprises natural sources of CBD and curcumin.  4. The composition of claim 1 , wherein the natural source of CBD comprises CBD producing hemp and the natural source of curcumin comprises turmeric.
  • 29. Patent case study 5. The composition of claim 4, wherein the CBD comprises a liquid or a powder extract of a cannabis plant and the curcumin comprises a liquid or a powder extract from a turmeric root. 6. The composition of claim 5, wherein the CBD extract comprises at least 80% (w/w) CBD to total cannabinoid content. 7. The composition of claim 5, wherein the curcumin extract comprises at least 2% by weight curcuminoid content. 8. The composition of claim 5, wherein the weight ratio of CBD extract to curcumin extract comprises about 1 : 1 to about 1 :5.
  • 30. Patent case study 9. The composition of claim 5, wherein the weight ratio of CBD in the CBD extract and curcuminoid in the curcumin extract comprises about 1 : 1 to about 1 : 10. 10. The composition of claim 5, wherein the composition comprises a water soluble dosage form. 11. The dosage form of claim 10, wherein the dosage form comprises a capsule, tablet or liquid. 12. The dosage form of claim 11 , wherein the dosage form comprises a capsule.
  • 31. Patent case study 13. A method of treating pain comprising: a) selecting a patient in need of treatment for pain; b) administering to the patient a therapeutically effective amount of CBD and curcumin, wherein the patient is treated. 14. The method as claimed in claim 13, wherein the pain comprises acute pain, chronic pain, or acute and chronic pain. 15. A method of treating pain comprising administering to a patient the composition of claim 1. 16. A method of treating pain comprising administering to a patient the composition of claim 2.
  • 32. Patent case study 17. A method of treating pain comprising administering to a patient the composition of claim 4. 18. A method of treating pain comprising administering to a patient the composition of claim 5. 19. A method of treating pain comprising administering to a patient the capsule of claim 12.
  • 33. Schedule T The Good Manufacturing Practices (GMP) are prescribed as follows in Part I and Part II to ensure that: I. Raw materials used in the manufacture of drugs are authentic, of prescribed quality and are free from contamination. II. The manufacturing process is as has been prescribed to maintain the standards. III. Adequate quality control measures are adopted. IV. The manufactured drug which is released for sale is of acceptable quality.
  • 34. Schedule T V. To achieve the objectives listed above, each licensee shall evolve methodology and procedures for following the prescribed process of manufacture of drugs which should be documented as a manual and kept for reference and inspection. However, under IMCC Act 1970 registered Vaidyas, Siddhas and Hakeems who prepare medicines on their own to dispense to their patients and not selling such drugs in the market are exempted from the purview of G.M.P.
  • 35. Schedule T  PART-I  GOOD MANUFACTRING PRACTICES  Factory Premises:  The manufacturing plant should have adequate space for:- (i) Receiving and storing raw material (ii) Manufacturing process areas (iii) Quality control section (iv) Finished goods store (v) Office (vi) Rejected goods/drugs store
  • 36. Schedule T  General Requirements:  Location and surroundings  Buildings  Water supply  Disposal of waste  Containers’ cleaning  Stores  Raw materials  Packaging material  Finished goods stores
  • 37. Schedule T  Working space  Heath, clothing, sanitation and hygiene of workers  Medical services  Machinery and equipment's  Batch manufacturing records  Distribution records  Record of market complaints  Quality control
  • 38. Schedule T  Requirement for Sterile product  Manufacturing areas  Precautions against contamination and mix
  • 39. Schedule T  Requirement for Space for ASU  200 sq. feet: Asava, Arishta, Churna / Nasya/Manjan/Lepa/Kwath Churn Sufoof (powder)  150 sq. feet: Kupi pakava/Ksara/ Parpati/Lavana Bhasma Satva/Sindura Karpu/ Uppu /Param, Panak, Syrup / Pravahi Kwath Manapaku,  100 sq. feet: Anjana/Pisti, Pills/Vati /Gutika, Matirai and tablets, Kajal, Capsule, Marham, ointment, Pak/Avaleh/Khand/ Modak/Lakayam, Ark Tinir, Sura, Taila, Ghrit ney, Aschyotan / Netra Malham, Panir/Karn Bindu/Nasabindu, Habb (Pills) and tablets, Arq,
  • 40. Schedule Y for Herbal Drugs  All of the fundamental ethical principles of human participation in research apply equally to herbal remedies and research involving these compounds.  Consent must be obtained, subject selection must be equitable, risks and benefits must be weighed and must be favourable to the potential participant, and experimental design must be sound.  Concerns that particularly apply to clinical trials with herbal products include:  Product adulteration (has it been documented?)  Interactions between herbal remedies and other entities (rarely understood)  Reproductive and organ toxicity data (may be minimal)  Prior dose finding (likely to be incomplete).
  • 41. Schedule Y for Herbal Drugs  Category 1: already in use for more than 5 years  Category 2: in use for less than 5 years  Category 3: new medicines.  For the herbal remedies and medicinal plants that are to be clinically evaluated for use in the Allopathic System and which may later be used in allopathic hospitals, the procedures laid down by the office of the Drugs Controller General of India for allopathic drugs should be followed.  When an extract of a plant or a compound isolated from the plant has to be clinically evaluated for a therapeutic effect not originally described in the texts of traditional systems or, the method of preparation is different, it has to be treated as a new substance or new chemical entity (NCE) and the same type of acute, sub acute and chronic toxicity data will have to be generated as required by the regulatory authority before it is cleared for clinical evaluation.
  • 42. Schedule Y for Herbal Drugs  An extract or a compound isolated from a plant, which has never been in use before and has not ever been mentioned in ancient literature, should be treated as a new drug, and therefore, should undergo all regulatory requirements before being evaluated clinically.  The document also provides general guidelines on clinical trials of herbals, toxicity studies, need for standardization, and compliance with GCP in all clinical trials.  Some of the recommendations are:  Clinical trials should be carried out with herbal preparations only after standardization and identification of markers to ensure that the substances being evaluated are always the same.  Plants and herbal remedies should be prepared strictly in the same way as described in the literature while incorporating GMP norms for standardization.
  • 43. Schedule Y for Herbal Drugs  Herbal remedies, Phase 1 studies must be undertaken to check Maximum tolerarated dose (MTD) & Early Measurement of Drug activity.  If there are reports suggesting toxicity or when the herbal preparation is to be used for more than 3 months, toxicity studies (4-6 weeks toxicity study in 2 species) are needed for phase 2 trials.  For Phase 3 trial toxicity studies (4-6 weeks toxicity study in 2 species) are needed.  Ethical guidelines (patient information, informed consent, protection of vulnerable populations etc) for biomedical research should be followed.  Clinical trials should to be approved by the appropriate scientific and ethical committees of the concerned Institutes.  Clinical trials should be carried out only when a competent Ayurvedic, Siddha or Unani physician is a co-investigator.
  • 44. Herbal Drug Regulations  Schedule Z: Proposed: Requirements and Guidelines for permission to manufacture of ASU Drugs for sale or to undertake clinical trials  Updated shelf life
  • 45. Marker standardization  Volatile Oil: Eugenol  Glycoside: Digitoxin  Resin: Curcumin  Flavonoids: Quercetin  Irridoids: Gentiopicroside
  • 46. Marker standardization Volatile Oil: Eugenol  Species: Cinnamomum zeylanicum  Eugenia caryophyllus  TLC Mobile Phase  Toluene: Ethyl acetate (93:7)  Detection: Vanillin H2SO4 & Visible light  Observation: Pinkish red spot  Rf value: 0.9  Eugenol oil on treatment with KOH, produces Potassium eugenate crystals
  • 47. Marker standardization Glycoside: Digitoxin  Species: Digitalis lanata  Digitalis purpurea  TLC Mobile Phase  Ethyl acetate: Methanol: Water (81:11:8)  Detection: Kedde reagent & Visible light  Observation: Grey to Violet grey color spot  Detection: SbCl3 & UV-365  Observation: Dark blue fluorescence  Rf value: 0.05-0.95  Keller-killiani test for Cardiac glycoside
  • 48. Marker standardization Glycoside: Glycyrrhizin (K+ salt)  Species: Glycyrrhiza glabara  TLC Mobile Phase  Chloroform: Methanol: Water (64:50:10)  Detection: UV 254 nm  Rf value: 0.25-0.3- Glycyrrhizin  Detection: Anisaldehyde H2SO4 reagent  Observation: Pink-violet spot  Rf value: 0.24- Glycyrrhizin  0.6-0.8 - Liquiritin
  • 49. Marker standardization Resin: Curcumin  Species: Curcuma longs  Curcuma domestica  TLC Mobile Phase  Cholorofrom: Ethanol: Glacial acetic acid (95:5:1)  Detection: UV-365  Observation: Yellow  Rf value: 0.3 – bisdemethoxycurcumin  0.5-0.55 – demethoxycurcumin  0.6 – curcumin
  • 50. Marker standardization Flavonoids: Rutin  Species:  TLC Mobile Phase  Ethyl acetate: Formic acid: Glacial acetic acid: Water (100:11:11:26)  Detection: UV-365  Observation: Yellow orange  Rf value: 0.4 – Rutin  Shinoda test for Flavonoids
  • 51. Marker standardization Irridoids: Gentiopicroside  Species: Gentiana lutea  TLC Mobile Phase  Ethyl acetate: Methanol: Water (77:15:8)  Detection: Vanillin H2SO4 & Visible light  Observation: brown-violet spot  Rf value: 0.45 (gentiopicroside)  Detection: UV 245 nm  Rf value: 0.4 – swetiamarine  0.45 – gentiopicroside  0.8 – amarogentin